News
Maciej Wieczorek on Twarze Biznesu (The Faces of Business) show at Onet.pl and Forbes.pl
Does working in a bank teach you discipline? What was the Polish pharmaceutical sector like in the 1990s and what is the entrepreneurial ethos? Maciej Wieczorek was a guest on a show called Twarze Biznesu (The Faces of Business) hosted by Michał Broniatowski. We encourage you to watch the entire video. http://biznes.onet.pl/wiadomosci/medycyna/twarze-biznesu-lek-na-raka-od-polskiego-milionera/drx6dj
Celon Pharma S.A. at BioForum 2016
On 9 and 10 May 2016 Celon Pharma S.A. representatives will participate in this year’s edition of BioForum, the most important event in biotechnology in Poland. This year BioForum will be held in the city of Lodz. For the fifteenth time the event will bring together representatives of business and science associated with the broadlyRead more »
Celon Pharma S.A. is a partner of the “Aurelius Awards”
The Second International Congress of Forensic Psychiatry took place on 15-16 April 2016. The “Aurelius Awards” were conferred during the event. The initiative was supported by Celon Pharma S.A. The aim of the “Aurelius Awards” is to recognise individuals who work to improve the quality of life of the mentally ill and who introduce aRead more »
Another innovative cancer project coordinated by the Celon Pharma S.A. Research and Development Centre has been launched
On 30 March this year the inaugural meeting was held for the research project: Development of modern biomarkers and development of an innovative FGFR kinase inhibitor for the treatment of neoplastic diseases – CELONKO; the meeting offered the project participants the chance to learn the main assumptions and current status of the project.
Celon Pharma hosts a meeting of the Polish Innovative Neuromedicine Platform
On 18 March Celon Pharma S.A. hosted another meeting of “InnoNeuroMed”, the Polish Innovative Neuromedicine Platform. The theme of the meeting was: different aspects of affective disorders. The meeting was attended by members of the Platform representing leading scientific institutions and pharmaceutical companies working in the field of neuromedicine in Poland.
Another innovative neurological research project carried out in Celon Pharma S.A. laboratories with support from the National Centre for Research and Development
The project entitled “New S-ketamine therapy for treatment-resistant depression” aims to develop a technology for a new route of ketamine administration in patients suffering from severe forms of treatment-resistant depression. Katamine is a well-known and widely used general anaesthetic. Recently, the possibility of its use in treatment of severe episodes of treatment-resistant depressionRead more »
Celon Pharma S.A. signed an agreement with Glemnark Pharmaceutical Europe Limited on commercialisation of Salmex into several European countries.
Celon Pharma S.A. signed an agreement with Glemnark Pharmaceutical Europe Limited on commercialisation of Salmex into several European countries. The company concluded an agreement under which it undertakes to, inter alia, supply a pharmaceutical product approved for marketing in selected European markets. The distribution agreement was concluded for a period of 10 years, with anRead more »
Celon Pharma S.A. and the National Science Centre supports young scientists
Celon Pharma S.A. recognised the most outstanding researcher in the field of life sciences by awarding a scholarship in a contest organised by the National Science Centre (NCN). The ceremony took place on 7 October 2015 in the Kraków Cloth Hall. The award was granted to Wiesław Babik PhD, whose outstanding achievements in the fieldRead more »
Celon Pharma S.A. research results on European Respiratory Society Congress
Celon Pharma S.A. researchers will attend ERS Annual Congress that will be held from 6th to 10th of September 2014 in Munich. We will take this opportunity to present the latest data on innovative small-molecule inhibitors of JAK/STAT pathway and PI3Kd kinase which are being developed in our laboratories as potential therapeutics for asthma andRead more »